Patent ID: 6653332
Filing Date: 2003-11-25
Classification: A61K,A61P,Y10S

Abstract:
A method for modulating medical conditions associated with metabolic disorders, said method comprising administering to a host an efficacious amount of(i) a compound having the formula: wherein Ar1 is an aryl group; X is a divalent linkage selected from the group consisting of (C1-C6)alkylene, (C1-C6)alkylenoxy, (C1-C6)alkylenamino, (C1-C6)alkylene-S(O)kâ€”, â€”Oâ€”, â€”C(O)â€”, â€”N(R11)â€”, â€”N(R11)C(O)â€”, â€”S(O)kâ€” and a single bond, wherein R11 is a member selected from the group consisting of hydrogen, (C1-C8)alkyl, (C1-C8)heteroalkyl and aryl(C1-C4)alkyl; and the subscript k is an integer of from 0 to 2; Y is a divalent linkage selected from the group consisting of alkylene, â€”Oâ€”, â€”C(O)â€”, N(R12)â€”S(O)mâ€”, â€”N(R12)S(O)mâ€”N(R13)â€”, â€”N(R12)C(O)â€”, â€”S(O)nâ€” and a single bond, wherein R12 and R13 are members independently selected from the group consisting of hydrogen, (C1-C8)alkyl, (C1-C8)heteroalkyl and aryl(C1-C4)alkyl; and the subscripts m and n are independently integers of from 0 to 2; R1 is a member selected from the group consisting of hydrogen, heteroalkyl, aryl, arylalkyl, halogen, cyano, nitro, (C1-C8)alkyl, (C1-C8)alkoxy, â€”C(O)R14, â€”CO2R14, â€”C(O)NR15R16, â€”S(O)pâ€”R14, â€”S(O)qâ€”NR15R16, â€”Oâ€”C(O)OR17, â€”Oâ€”C(O)R17,â€”Oâ€”C(O)NR15R16, â€”N(R14)â€”C(O)â€”NR15R16, â€”N(R14)â€”C(O)â€”R17 and â€”N(R14)â€”C(O)â€”OR17; wherein R14 a member selected from the group consisting of hydrogen, (C1-C8)alkyl, (C1-C8)heteroalkyl, aryl and aryl(C1-C4)alkyl; R15 and R16 are members independently selected from the group consisting of hydrogen, (C1-C8)alkyl, (C1-C8)heteroalkyl, aryl, and aryl(C1-C4)alkyl, or taken together with the nitrogen to which each is attached form a 5-, 6- or 7-membered ring; R17 is a member selected from the group consisting of alkyl, heteroalkyl, aryl and arylalkyl; the subscript p is an integer of from 0 to 3; and the subscript q is an integer of from 1 to 2; and R2 is a member selected from the group consisting of (C1-C8)alkyl, (C1-C8)heteroalkyl, aryl and aryl(C1-C4)alkyl; and R3 is a member selected from the group consisting of halogen, cyano, nitro, and (C1-C8)alkoxy; and ii) at least one therapeutically active agents or a prodrug thereof, or a pharmaceutically acceptable salt of said agent, and a pharmaceutically acceptable carrier or diluent.